Full-Time

Director of Quality Assurance Operations

Adicet Bio

Adicet Bio

51-200 employees

Off-the-shelf gamma delta T therapies

Compensation Overview

$199k - $274k/yr

+ Annual Bonus + Equity

San Carlos, CA, USA

In Person

Onsite required at least three days per week (Tuesday–Thursday).

Bachelor's

Category
QA & Testing (1)

Get referred to Adicet Bio

See people who can refer or advise you

Requirements
  • Bachelor’s Degree in scientific or relevant disciplines in life sciences
  • 10+ years of experience within the life sciences industry, preferably biotechnology, pharmaceuticals, or other regulated therapeutic environment with 6+ years in a Quality Assurance role
  • 5+ years of direct management experience
  • Demonstrated mastery of cGMP regulations and quality systems
  • Thorough knowledge of applicable regulatory requirements (FDA CFR, EMA, ICH, ISO, any other global laws/regulations)
  • Experience with Health Authority Inspections
  • Proficiency with electronic management systems (such as LIMS, eQMS,)
  • Strong interpersonal and communication skills: written and oral
  • Outstanding planning, organization, and multitasking skills
  • Travel as required
  • Prior cell therapy experience is a plus
Responsibilities
  • Ensure current Good Manufacturing Practices (cGMPs) compliance for clinical manufacturing of phase I/II/III investigational product, and compliance to 21 CFR Parts 210, 211, ICH Guidelines and EU GMPs as applicable
  • Accountable for lot disposition activities including batch record review, in-process/release and stability testing review, oversight of quality events relating to GMP product, process, or facility, etc. Will lead by example to partner with cross functional groups to meet company objectives in compliance with applicable regulatory guidelines
  • Review approval of development activities in preparation for GMP such as development studies/reports, engineering activities, etc.
  • Collaborates with cross functional teams and champions the Quality Risk Management Program
  • Responsible for the phase appropriate validation program
  • Serves as team leader in quality related discussions, investigations, risk assessments, change controls, etc. to resolve potential product quality issues and to ensure they are appropriately addressed and justified
  • Partners with Facilities and functional SMEs to support equipment qualifications and lifecycle management
  • Collaborates with Quality Systems to manage the cGxP training program for internal manufacturing related functions
  • Represents the organization during third-party audits and inspections as required
  • Provides technical expertise and guidance in conducting investigations in regard to quality deviations, laboratory investigations/change controls systems for tracking statuses, follow-up, and liaison with applicable department investigation writers to ensure their complete and timely resolution
  • Provides oversight for the raw material program, including raw material QA release
  • Develop and implement procedures, programs and policies that support quality assurance functions and assure cGxP compliance
  • Supports regulatory submissions of quality related sections
  • Be a champion for continuous improvement. Identifies and drives continuous improvement initiatives and monitors progress of deliverables
  • Other duties as required
Desired Qualifications
  • Prior cell therapy experience is a plus

Adicet Bio develops cancer immunotherapies using donor-derived, allogeneic gamma delta T cells that are engineered to target and kill cancer cells. The therapy uses off-the-shelf cells instead of a patient’s own cells, making treatment faster and potentially more readily available. The product works by introducing these modified T cells into a patient, where they seek out and destroy tumor cells. Adicet Bio differentiates itself by providing an immediately available, genetically modified immune cell therapy rather than patient-specific treatments, and by focusing on gamma delta T cells, which may offer targeted anti-tumor activity with a different safety and efficacy profile. The company aims to bring these therapies to patients through commercialization, licensing, and partnerships with healthcare providers and larger pharma companies, supported by ongoing research and development and strategic initiatives like the merger with resTORbio and a substantial funding round.

Company Size

51-200

Company Stage

IPO

Headquarters

Redwood City, California

Founded

2014

Get referred to Adicet Bio

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • August 5, 2026 cash was $118.2 million, funding operations into 2H 2027.
  • Q3 2026 prula-cel data should cover 22 lupus patients with 12-month follow-up.
  • ADI-212 filing is planned for Q3 2026, opening a new PSMA oncology path.

What critics are saying

  • August 3, 2026 CMO Julie Maltzman resigned; interim coverage weakens clinical execution.
  • July 2025 ADI-270 shutdown and 30% layoffs exposed brittle pipeline concentration.
  • If prula-cel stalls in 2H 2026, Adicet faces another dilutive financing cycle.

What makes Adicet Bio unique

  • Adicet’s prula-cel uses allogeneic gamma delta T cells, not patient-specific manufacturing.
  • January 7, 2026 FDA alignment enabled outpatient prula-cel dosing in lupus patients.
  • MaxCyte’s August 4, 2025 platform license supports Adicet’s gene-edited manufacturing and scale.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Flexible Work Hours

Paid Vacation

Paid Sick Leave

Paid Holidays

Parental Leave

401(k) Retirement Plan

401(k) Company Match

Employee Stock Purchase Plan

Wellness Program

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-2%

2 year growth

3%
BioSpace
Jul 22nd, 2026
Adicet Bio to participate in fireside chat at Canaccord Genuity 46th Annual Growth Conference.

Adicet Bio to participate in fireside chat at Canaccord Genuity 46th Annual Growth Conference. July 22, 2026 | REDWOOD CITY, Calif.-(BUSINESS WIRE)-Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference being held from August 11-13, 2026, in Boston. Details of the event are as follows: Date: Tuesday, August 11, 2026 Time: 10:30 a.m. ET The live audio webcast can be accessed on the Investors section of Adicet Bio's website at https://www.adicetbio.com. An archived replay will be available for 30 days following the presentation. About Adicet Bio, Inc. Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of "off-the-shelf" gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at https://www.adicetbio.com. Adicet Bio, Inc. Investor and Media Contacts Anne Bowdidge [email protected] Penelope Belnap Precision AQ [email protected]

Adicet Bio
Jul 21st, 2026
Adicet Bio to participate in fireside chat at Canaccord Genuity 46th Annual Growth Conference.

Adicet Bio to participate in fireside chat at Canaccord Genuity 46th Annual Growth Conference. REDWOOD CITY, Calif.-(BUSINESS WIRE)-Jul. 21, 2026- Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference being held from August 11-13, 2026, in Boston. Details of the event are as follows: Date: Tuesday, August 11, 2026 Time: 10:30 a.m. ET The live audio webcast can be accessed on the Investors section of Adicet Bio's website at https://www.adicetbio.com. An archived replay will be available for 30 days following the presentation. About Adicet Bio, Inc. Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of "off-the-shelf" gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit its website at https://www.adicetbio.com. Adicet Bio, Inc. Investor and Media Contacts Anne Bowdidge [email protected] Penelope Belnap Precision AQ [email protected]

TipRanks
Jan 7th, 2026
Adicet Bio doubles prula-cel Phase 1 enrolment, extends cash runway to 2027 with $75M raise

Adicet Bio has expanded enrollment in its Phase 1 prula-cel programme for autoimmune diseases to over 20 patients as of 31 December 2025, more than doubling since October. All seven autoimmune cohorts are now actively enrolling, including the first ANCA-associated vasculitis patient. The company has secured FDA alignment for outpatient dosing of lupus nephritis and systemic lupus erythematosus patients. Adicet is also advancing ADI-212 for metastatic castration-resistant prostate cancer, targeting a regulatory filing in the first half of 2026. An October 2025 equity raise of approximately $74.8 million has extended the company's cash runway into the second half of 2027. Multiple clinical data updates are planned throughout 2026 as Adicet works towards a pivotal trial design.

Investing.com
Oct 7th, 2025
Adicet Bio $80M Stock Offering Announced

Adicet Bio (NASDAQ:ACET) announced an $80 million stock offering, pricing 70,001,000 shares at $1 each and pre-funded warrants for 10 million shares at $0.9999. The offering, expected to close by October 8, 2025, aims to bolster finances amid rapid cash burn. Jefferies and Guggenheim Securities are joint book-running managers. Adicet also reported positive results from its ADI-001 trial and halted ADI-270 development, reducing its workforce by 30% to extend cash reserves into Q4 2026.

BioProcess International
Aug 13th, 2025
Auspicious alliance: MaxCyte and Adicet partner to develop off-the-shelf T-cell therapies

Auspicious alliance: MaxCyte and Adicet partner to develop off-the-shelf T-cell therapies.